Xoma Corporation

Xoma Technology Ltd.

Research Development Foundation

Xoma (us) LLC

Marc D Better

Shau-Ping Lei

Randy R Robinson

Arnold H Horwitz

Stephen Fitzhugh Carroll

Gary L Wilcox

Alvin Y Liu

Gary M Studnicka

Randolph Wall

Changtung Paul Chang

Patrick Gavit

Susan L Bernhard

Julie A Lane

Steve F Carroll

Patrick D Gavit

Arnold H Horowitz

The present invention provides improved methods for the production of recombinant peptides from bacterial cells.

Methods for recombinant peptide production

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

Immunotoxins comprising ribosome-inactivating proteins

The present invention relates generally to improved methods for the expression of recombinant protein products under the transcriptional control of an inducible promoter, such as an araB promoter, in bacterial host cells that are deficient in one or more of the active transport systems for the inducer of the inducible promoter. The present invention also relates to improved bacterial host cells that are deficient in one or more of the active transport systems for an inducer of an inducible promoter, such as arabinose for an araB promoter, and contain an expression vector encoding a recombinant polypeptide under the transcriptional control of the inducible promoter, such as an araB promoter.

Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoter

The invention is directed to chimeric immunoglobulins that recognize a human tumor antigen bound by antibody, ING-2, ING-3, ING-4 or KM10, the production of such chimeric immunoglobulins, and their use.

Production of chimeric antibodies with specificity to human tumor antigens

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

Fusion proteins and polynucleotides encoding gelonin sequences

The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).

Methods for recombinant microbial production of fusion proteins and BPI-derived peptides

The present invention provides improved methods for the production of recombinant peptides from bacterial cells in which acid Lysis of the peptide occurs in cell culture media.

Modular assembly of antibody genes, antibodies prepared thereby and use

The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.

Proteins encoding gelonin sequences

Methods for recombinant microbial production of fusion proteins and

The invention is directed to the pectate lyase B secretion signal and its use to express operably linked sequences in bacterial hosts.

Growing community of inventors

Los Angeles, CA, United States of America

Marc D Better